BidaskClub Downgrades ANI Pharmaceuticals (ANIP) to Buy

BidaskClub cut shares of ANI Pharmaceuticals (NASDAQ:ANIP) from a strong-buy rating to a buy rating in a report published on Tuesday, BidAskClub reports.

A number of other equities analysts have also weighed in on the stock. Canaccord Genuity restated a buy rating and set a $90.00 price target (up from $80.00) on shares of ANI Pharmaceuticals in a research report on Monday, May 13th. Raymond James lowered shares of ANI Pharmaceuticals from a strong-buy rating to an outperform rating and boosted their price target for the stock from $73.00 to $82.00 in a research report on Friday, May 10th. ValuEngine upgraded shares of ANI Pharmaceuticals from a hold rating to a buy rating in a report on Thursday, May 9th. Cantor Fitzgerald reiterated a buy rating and issued a $89.00 target price on shares of ANI Pharmaceuticals in a report on Thursday, May 9th. Finally, Zacks Investment Research lowered shares of ANI Pharmaceuticals from a strong-buy rating to a hold rating in a report on Tuesday, April 30th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company presently has an average rating of Buy and an average price target of $84.50.

ANIP opened at $69.92 on Tuesday. The stock has a market cap of $847.80 million, a P/E ratio of 15.04 and a beta of 2.37. ANI Pharmaceuticals has a twelve month low of $36.92 and a twelve month high of $74.00. The company has a current ratio of 0.92, a quick ratio of 0.67 and a debt-to-equity ratio of 0.33.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.25. The firm had revenue of $52.90 million for the quarter, compared to analyst estimates of $50.57 million. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. ANI Pharmaceuticals’s quarterly revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the business posted $1.32 earnings per share. Equities analysts predict that ANI Pharmaceuticals will post 5.57 EPS for the current year.

In other ANI Pharmaceuticals news, SVP Robert W. Schrepfer sold 2,409 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $71.13, for a total value of $171,352.17. Following the transaction, the senior vice president now directly owns 55,927 shares in the company, valued at approximately $3,978,087.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Arthur Przybyl sold 9,595 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $71.10, for a total transaction of $682,204.50. Following the completion of the transaction, the chief executive officer now owns 222,994 shares in the company, valued at $15,854,873.40. The disclosure for this sale can be found here. Insiders sold a total of 74,280 shares of company stock worth $5,010,337 over the last quarter. 24.70% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the business. Dimensional Fund Advisors LP boosted its holdings in ANI Pharmaceuticals by 3.2% in the 1st quarter. Dimensional Fund Advisors LP now owns 534,993 shares of the specialty pharmaceutical company’s stock valued at $37,737,000 after purchasing an additional 16,566 shares during the last quarter. Vanguard Group Inc raised its stake in shares of ANI Pharmaceuticals by 1.6% in the 3rd quarter. Vanguard Group Inc now owns 522,813 shares of the specialty pharmaceutical company’s stock valued at $29,559,000 after acquiring an additional 8,173 shares during the period. Vanguard Group Inc. raised its stake in shares of ANI Pharmaceuticals by 1.6% in the 3rd quarter. Vanguard Group Inc. now owns 522,813 shares of the specialty pharmaceutical company’s stock valued at $29,559,000 after acquiring an additional 8,173 shares during the period. First Manhattan Co. raised its stake in shares of ANI Pharmaceuticals by 2.2% in the 1st quarter. First Manhattan Co. now owns 240,166 shares of the specialty pharmaceutical company’s stock valued at $16,941,000 after acquiring an additional 5,171 shares during the period. Finally, Investment Counselors of Maryland LLC raised its stake in shares of ANI Pharmaceuticals by 771.6% in the 4th quarter. Investment Counselors of Maryland LLC now owns 207,300 shares of the specialty pharmaceutical company’s stock valued at $9,333,000 after acquiring an additional 183,515 shares during the period. Institutional investors own 60.02% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.

Further Reading: What are CEFs?

Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.